Zobrazeno 1 - 10
of 146
pro vyhledávání: '"Hiromichi NAKAJIMA"'
Autor:
Kaede Baba, Megumi Kawamoto, Kanako Mamishin, Mao Uematsu, Hikari Kiyohara, Akira Hirota, Nobuyuki Takahashi, Misao Fukuda, Shota Kusuhara, Hiromichi Nakajima, Chikako Funasaka, Takehiro Nakao, Chihiro Kondoh, Kenichi Harano, Nobuaki Matsubara, Yoichi Naito, Ako Hosono, Toshikatsu Kawasaki, Toru Mukohara
Publikováno v:
Cancer Medicine, Vol 12, Iss 11, Pp 12095-12105 (2023)
Abstract Background Since it was first reported in December 2019, coronavirus disease 2019 (COVID‐19) spread rapidly across the globe resulting in a pandemic. As of August 2022, seven outbreak peaks have been confirmed in Tokyo, and the numbers of
Externí odkaz:
https://doaj.org/article/c0255b117bae403e9d5e854df13ba152
Autor:
Hiromichi Nakajima, Kenichi Harano, Tokiko Nakai, Shota Kusuhara, Takehiro Nakao, Chikako Funasaka, Chihiro Kondoh, Nobuaki Matsubara, Yoichi Naito, Ako Hosono, Shuichi Mitsunaga, Genichiro Ishii, Toru Mukohara
Publikováno v:
Breast, Vol 61, Iss , Pp 136-144 (2022)
Background: The previous second-line treatment for HER2-positive metastatic breast cancer were ado-trastuzumab emtansine (T-DM1); however, its activity is decreased in tumors with heterogenous, reduced, or loss of HER2 expression. Trastuzumab deruxte
Externí odkaz:
https://doaj.org/article/d024404aa0a9446f8558c9fcac6f4da6
Autor:
Hiromichi Nakajima, Daisuke Kotani, Hideaki Bando, Takeshi Kato, Eiji Oki, Eiji Shinozaki, Yu Sunakawa, Kentaro Yamazaki, Satoshi Yuki, Yoshiaki Nakamura, Takeharu Yamanaka, Takayuki Yoshino, Takashi Ohta, Hiroya Taniguchi, Yoshinori Kagawa
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-6 (2021)
Abstract Background Previous clinical trials have demonstrated the potential efficacy of rechallenge with anti- epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) for patients with RAS/BRAF V600E wild-type metastatic colorectal canc
Externí odkaz:
https://doaj.org/article/02b244cb3c0549f99cadc14324637692
Autor:
Hiromichi Nakajima, Tetsuya Nakatsura
Publikováno v:
Immunological Medicine, Vol 44, Iss 1, Pp 10-15 (2021)
Cancer immunotherapy has a long developmental history, beginning with William Coley’s first bacterial mixture (‘Coley’s toxin’) in 1891, which led to the development of nonspecific immunotherapy. After the research team of Thierry Boon succee
Externí odkaz:
https://doaj.org/article/96e458efd8a745478afe74117e76c52b
Autor:
Hiromichi Nakajima, Shota Fukuoka, Toshiki Masuishi, Atsuo Takashima, Yosuke Kumekawa, Takeshi Kajiwara, Kentaro Yamazaki, Yuji Negoro, Masato Komoda, Akitaka Makiyama, Tadamichi Denda, Yukimasa Hatachi, Takeshi Suto, Naotoshi Sugimoto, Masanobu Enomoto, Toshiaki Ishikawa, Tomomi Kashiwada, Koji Ando, Satoshi Yuki, Hiroyuki Okuyama, Hitoshi Kusaba, Daisuke Sakai, Koichi Okamoto, Takao Tamura, Kimihiro Yamashita, Masahiko Gosho, Toshikazu Moriwaki
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundPrimary tumor location (PTL) is an important prognostic and predictive factor in the first-line treatment of metastatic colorectal cancer (mCRC). Although regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) have been introduced recently,
Externí odkaz:
https://doaj.org/article/1b5c529d863847208161fdacda20bb31
Autor:
Yukinori Ozaki, Junichi Shindoh, Yuji Miura, Hiromichi Nakajima, Ryosuke Oki, Miyuki Uchiyama, Jun Masuda, Keiichi Kinowaki, Chihiro Kondoh, Yuko Tanabe, Tsuyoshi Tanaka, Shusuke Haruta, Masaki Ueno, Shigehisa Kitano, Takeshi Fujii, Harushi Udagawa, Toshimi Takano
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-7 (2017)
Abstract Background Pseudoprogression refers to a specific pattern of response sometimes observed in malignant melanoma patients receiving treatment with immune-checkpoint inhibitors. Although cases with pseudoprogression documented once have been re
Externí odkaz:
https://doaj.org/article/fb9230bd87e74a8c9714f87765757cbd
Autor:
Yoshikazu Ohara, Taro Oshiumi, Hiromichi Nakajima, Kazushi Yamanaka, Xiaoyang Wu, Tetsuya Uchimoto, Toshiyuki Takagi, Toshihiro Tsuji, Tsuyoshi Mihara
Publikováno v:
AIP Advances, Vol 7, Iss 6, Pp 065214-065214-7 (2017)
To accurately measure crack lengths, we developed a real-time surface imaging method (SAW PA) combining an ultrasonic phased array (PA) with a surface acoustic wave (SAW). SAW PA using a Rayleigh wave with a high sensitivity to surface defects was im
Externí odkaz:
https://doaj.org/article/400586706c204783aeeb386841d89d0a
Autor:
Tadashi HOSHINO, Tadashi ISHIHARA, Hiroshi OKADA, Ayako MATSUNAGA, Masahiro TSUBURA, Ryo TANABE, Sho KIMURA, Naruhiko ISHIWADA, Hiromichi NAKAJIMA
Publikováno v:
Kansenshogaku Zasshi. 97:18-25
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a149ed8b2d1d540490149dfd41885ec
https://doi.org/10.11150/kansenshogakuzasshi.e22030
https://doi.org/10.11150/kansenshogakuzasshi.e22030
Autor:
Chikako Funasaka, Yoichi Naito, Shota Kusuhara, Takehiro Nakao, Hiromichi Nakajima, Megumi Kawamoto, Kaede Baba, Kanako Mamishin, Chihiro Kondoh, Kenichi Harano, Nobuaki Matsubara, Ako Hosono, Tomoaki Sasaki, Toshikatsu Kawasaki, Toru Mukohara
Publikováno v:
Japanese Journal of Clinical Oncology. 53:105-114
Background Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are the standard treatment for advanced hormone receptor-positive breast cancer. Although interstitial lung disease is a rare (1–3.3%) but serious adverse event associated with CDK4/6 inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1104059874437cc3479bc7074f648fcc
https://doi.org/10.1093/jjco/hyac168
https://doi.org/10.1093/jjco/hyac168
Autor:
Mao Uematsu, Hiromichi Nakajima, Ako Hosono, Hikari Kiyohara, Akira Hirota, Nobuyuki Takahashi, Misao Fukuda, Shota Kusuhara, Takehiro Nakao, Chikako Funasaka, Chihiro Kondoh, Kenichi Harano, Nobuaki Matsubara, Yoichi Naito, Tetsuo Akimoto, Toru Mukohara
Publikováno v:
Melanoma Research; Dec2023, Vol. 33 Issue 6, p547-552, 6p